22 Chapter 1 REFERENCES 1. SKION. Kinderoncologie in cijfers. SKION Basisregistratie. Retrieved from: https://www.skion.nl/ info/4208/kinderoncologie-in-cijfers/, 2. Sachs L: The control of hematopoiesis and leukemia: from basic biology to the clinic. Proc Natl Acad Sci U S A 93:4742-9, 1996 3. Inaba H, Mullighan CG: Pediatric acute lymphoblastic leukemia. Haematologica 105:2524-2539, 2020 4. Kamps WA, van der Pal-de Bruin KM, Veerman AJ, et al: Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. Leukemia 24:309-19, 2010 5. Schimmer BP, Funder JW: Adrenocorticotropic Hormone, Adrenal Steroids, and the Adrenal Cortex, in Brunton LL, Hilal-Dandan R, Knollmann BC (eds): Goodman & Gilman’s: The Pharmacological Basis of Therapeutics, 13e. New York, NY, McGraw-Hill Education, 2017 6. Pearson OH, Eliel LP: Use of pituitary adrenocorticotropic hormone (ACTH) and cortisone in lymphomas and leukemias. J Am Med Assoc 144:1349-53, 1950 7. Inaba H, Pui CH: Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol 11:1096-106, 2010 8. Bostrom BC, Sensel MR, Sather HN, et al: Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children’s Cancer Group. Blood 101:3809-17, 2003 9. Reedijk AMJ, Coebergh JWW, de Groot-Kruseman HA, et al: Progress against childhood and adolescent acute lymphoblastic leukaemia in the Netherlands, 1990-2015. Leukemia 35:1001-1011, 2021 10. Veerman AJ, Kamps WA, van den Berg H, et al: Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol 10:957-66, 2009 11. Vrooman LM, Stevenson KE, Supko JG, et al: Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--DanaFarber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol 31:1202-10, 2013 12. Grossmann C, Almeida-Prieto B, Nolze A, et al: Structural and molecular determinants of mineralocorticoid receptor signalling. Br J Pharmacol 179:3103-3118, 2022 13. Kadmiel M, Cidlowski JA: Glucocorticoid receptor signaling in health and disease. Trends Pharmacol Sci 34:518-30, 2013 14. Ronzaud C, Loffing J, Bleich M, et al: Impairment of sodium balance in mice deficient in renal principal cell mineralocorticoid receptor. J Am Soc Nephrol 18:1679-87, 2007 15. Baker ME, Funder JW, Kattoula SR: Evolution of hormone selectivity in glucocorticoid and mineralocorticoid receptors. J Steroid Biochem Mol Biol 137:57-70, 2013 16. Koning A, Buurstede JC, van Weert L, et al: Glucocorticoid and Mineralocorticoid Receptors in the Brain: A Transcriptional Perspective. J Endocr Soc 3:1917-1930, 2019 17. Harmon JM, Norman MR, Fowlkes BJ, et al: Dexamethasone induces irreversible G1 arrest and death of a human lymphoid cell line. J Cell Physiol 98:267-78, 1979 18. Jia WY, Zhang JJ: Effects of glucocorticoids on leukocytes: Genomic and non-genomic mechanisms. World J Clin Cases 10:7187-7194, 2022
RkJQdWJsaXNoZXIy MTk4NDMw